Community post

US phage biotech company Intralytix received a Fast Track NIH SBIR contract to develop a universal, scale-independent AI-based platform for manufacturing high titer phage preparations for clinical applications. Intralytix will receive a Phase I award of $299,672, with an option for a Phase II award of $1,498,045.